Mereo Financial Statements From 2010 to 2022

MREO
 Stock
  

USD 1.15  0.06  4.96%   

Mereo Biopharma financial statements provide useful quarterly and yearly information to potential Mereo Biopharma Group investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mereo Biopharma financial statements helps investors assess Mereo Biopharma's valuation, profitability, and current liquidity needs.
We have found sixty-four available fundamental ratios for Mereo Biopharma, which can be analyzed and compared to other ratios and to its peers in the industry. We recommend to check Mereo Biopharma's last-minute fundamental drivers against the all of the trends between 2010 and 2022.
Mereo Biopharma Earnings Before Interest Taxes and Depreciation Amortization EBITDA are quite stable at the moment as compared to the past year. The company's current value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is estimated at 20.4 Million. Earnings before Tax is expected to rise to about 15.4 M this year, although the value of Average Assets will most likely fall to about 85.2 M.
  
Check Mereo Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mereo main balance sheet or income statement drivers, such as Consolidated Income of 13.7 M, Cost of Revenue of 16 M or Earning Before Interest and Taxes EBIT of 19.7 M, as well as many exotic indicators such as Asset Turnover of 0.35, Book Value per Share of 0.94 or Current Ratio of 6.98. Mereo financial statements analysis is a perfect complement when working with Mereo Biopharma Valuation or Volatility modules. It can also supplement Mereo Biopharma's financial leverage analysis and stock options assessment as well as various Mereo Biopharma Technical models . Additionally, see the analysis of Mereo Biopharma Correlation against competitors.

Mereo Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets117.3 M126.4 M89.5 M
Increasing
Slightly volatile
Cash and Equivalents75 M94.3 M50.7 M
Increasing
Very volatile
Investments2.2 M2.2 M2.5 M
Decreasing
Slightly volatile
Investments Current2.2 M2.2 M2.5 M
Decreasing
Slightly volatile
Property Plant and Equipment Net2.9 M2.5 M1.5 M
Increasing
Slightly volatile
Tax Assets830.3 K809 K5.2 M
Decreasing
Stable
Trade and Non Trade Receivables1.2 M1.4 M824.1 K
Increasing
Slightly volatile
Trade and Non Trade Payables3.3 M2.5 M2.4 M
Increasing
Slightly volatile
Goodwill and Intangible Assets31.5 M24.6 M29.1 M
Increasing
Slightly volatile
Total Liabilities43.2 M38.4 M25.1 M
Increasing
Slightly volatile
Shareholders Equity94.9 M88 M66 M
Decreasing
Slightly volatile
Current Assets83 M99.3 M58.9 M
Increasing
Very volatile
Assets Non Current34.4 M27.1 M30.7 M
Increasing
Slightly volatile
Current Liabilities14.3 M12.5 M8.7 M
Increasing
Slightly volatile
Liabilities Non Current28.9 M25.9 M16.4 M
Increasing
Slightly volatile
Tax Liabilities1.4 M1.4 M1.5 M
Decreasing
Slightly volatile
Total Debt19.7 M16.8 M11.6 M
Increasing
Slightly volatile
Debt Current638.4 K622 K3.2 M
Increasing
Stable
Debt Non Current16.7 M16.1 M9.2 M
Increasing
Slightly volatile
Shareholders Equity USD126.6 M117.3 M83.7 M
Decreasing
Stable
Cash and Equivalents USD99.5 M125.7 M64.7 M
Increasing
Stable
Total Debt USD26.1 M22.3 M15.2 M
Increasing
Slightly volatile

Mereo Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues32.6 M32.8 M35.9 M
Decreasing
Slightly volatile
Cost of Revenue16 M16.1 M17.6 M
Decreasing
Slightly volatile
Selling General and Administrative Expense16.8 M15.9 M13.4 M
Increasing
Slightly volatile
Research and Development Expense22.6 M23.6 M24.3 M
Decreasing
Stable
Operating Expenses44.2 M39.4 M38.8 M
Increasing
Slightly volatile
Interest ExpenseMM1.9 M
Increasing
Slightly volatile
Income Tax Expense1.6 M1.5 M(4.4 M)
Increasing
Slightly volatile
Consolidated Income13.7 M12.7 M(34 M)
Decreasing
Very volatile
Net Income13.7 M12.7 M(34 M)
Decreasing
Very volatile
Net Income Common Stock13.7 M12.7 M(34 M)
Decreasing
Very volatile
Weighted Average Shares587.5 M544.5 M178.8 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT19.7 M18.3 M(36.4 M)
Increasing
Very volatile
Revenues USD43.5 M43.8 M47.9 M
Decreasing
Slightly volatile
Net Income Common Stock USD18.3 M17 M(44.1 M)
Decreasing
Very volatile
Earning Before Interest and Taxes USD26.3 M24.4 M(47 M)
Decreasing
Very volatile
Gross Profit16.6 M16.7 M18.3 M
Decreasing
Slightly volatile

Mereo Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals116 K113 K7.9 M
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals40.8 M37.8 M12.1 M
Increasing
Slightly volatile
Net Cash Flow from Financing83.8 M77.7 M53.9 M
Decreasing
Stable
Issuance Repayment of Debt Securities (710.2 K)(692 K)M
Decreasing
Very volatile
Issuance Purchase of Equity Shares84.5 M78.3 M51.5 M
Decreasing
Stable
Net Cash Flow from Investing(432.1 K)(421 K)3.3 M
Increasing
Stable
Effect of Exchange Rate Changes on Cash (1.2 M)(1.2 M)841.2 K
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents77.7 M72 M30.4 M
Decreasing
Very volatile
Share Based Compensation3.1 M3.3 M4.7 M
Decreasing
Slightly volatile
Depreciation Amortization and Accretion716.7 K642 K372.3 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share0.08630.08(1.9226)
Increasing
Slightly volatile
Earnings per Basic Share USD0.110.107(2.4274)
Increasing
Slightly volatile
Return on Average Equity0.380.348(1.4015)
Decreasing
Stable
Return on Average Assets0.140.134(0.4731)
Decreasing
Very volatile
Return on Invested Capital1.361.261(2.383)
Increasing
Slightly volatile
Gross Margin0.460.460.5013
Decreasing
Slightly volatile
Profit Margin0.310.310.343
Decreasing
Slightly volatile
EBITDA Margin0.470.470.5105
Decreasing
Slightly volatile
Return on Sales0.450.450.493
Decreasing
Slightly volatile
Asset Turnover0.350.350.3794
Decreasing
Slightly volatile
Enterprise Value over EBITDA4.043.744(0.5648)
Increasing
Slightly volatile
Enterprise Value over EBIT4.324.0(0.2065)
Increasing
Slightly volatile
Price to Earnings Ratio16.1815.01.0649
Increasing
Slightly volatile
Sales per Share0.320.320.3514
Decreasing
Slightly volatile
Price to Sales Ratio4.014.034.4089
Decreasing
Slightly volatile
Price to Book Value2.01.8560.0067
Decreasing
Stable
Debt to Equity Ratio0.470.437(0.0684)
Decreasing
Stable
Current Ratio6.987.9212.3587
Decreasing
Slightly volatile
Book Value per Share0.940.6462.1664
Decreasing
Slightly volatile
Tangible Assets Book Value per Share1.070.7482.2643
Decreasing
Slightly volatile

Mereo Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax15.4 M14.2 M(38.3 M)
Decreasing
Very volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA20.4 M18.9 M(36 M)
Increasing
Very volatile
Earnings Before Interest Taxes and Depreciation Amortization USD27.2 M25.2 M(46.5 M)
Increasing
Very volatile
Market Capitalization226.4 M217.8 M102.4 M
Increasing
Slightly volatile
Enterprise Value134.5 M94.4 M88.5 M
Increasing
Slightly volatile
Invested Capital16.2 M11.8 M12.6 M
Increasing
Slightly volatile
Average Equity36.4 M36.5 M56.7 M
Decreasing
Slightly volatile
Average Assets85.2 M94.7 M88.1 M
Decreasing
Slightly volatile
Invested Capital Average18.5 M14.5 M17.2 M
Increasing
Slightly volatile
Tangible Asset Value85.8 M101.9 M60.4 M
Increasing
Stable
Working Capital68.6 M86.8 M50.2 M
Decreasing
Stable

Mereo Fundamental Market Drivers

Forward Price Earnings-0.02
Shares Short Prior Month3.56M
Average Daily Volume Last 10 Day1.28M
Average Daily Volume In Three Month5.55M
Date Short Interest15th of July 2022
Fifty Day Average1.1574
Two Hundred Day Average1.3132

Mereo Upcoming Events

Upcoming Quarterly Report30th of March 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End30th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Mereo Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Mereo Biopharma income statement, its balance sheet, and the statement of cash flows. Mereo Biopharma investors use historical funamental indicators, such as Mereo Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Mereo Biopharma investors may use each financial statement separately, they are all related. The changes in Mereo Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Mereo Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Mereo Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Mereo Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Cost of Revenue16.1 M16 M
Revenues32.8 M32.6 M
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mereo Biopharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Shere Portfolio Now

   

Shere Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Mereo Biopharma Correlation against competitors. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
138 M
Return On Assets
-0.14
Return On Equity
0.35
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.